| Study (author, year) |
Source (database) |
Modeling method |
Main strategy tested |
Base strategy |
Clinical outcome |
Economic outcome |
Perspective of the paying source |
Main result £ |
| Caetano et al. (2006) [6] |
LILACS |
Markov model |
Population screening with hybrid capture |
Population screening with OC |
Number of cases detected |
R$/QALY |
Brazilian Unified Health System |
Base Strategy |
| Vanni et al. (2007) [10] |
MEDLINE |
Markov model |
Perform hybrid capture for patients with ASC-US |
Repeat OC in 6 months for patients with ASC-US |
Years of life saved |
US$/years of life saved |
Brazilian Unified Health System |
$ 1,914/year of life saved |
| Goldie et al. (2007) [19] |
MEDLINE |
Dynamictransition model |
Mass vaccination of pre-adolescents against HPV |
Population screening with OC |
Years of life saved |
US$/years of life saved |
Brazilian Unified Health System |
$ 1,100/year of life saved |
| Kok et al. (2007) [28] |
MEDLINE |
Dynamic transition model |
Mass vaccination of pre-adolescent boys and girls against HPV |
Mass vaccination of only pre-adolescent girls against HPV |
Years of life saved |
US$/years of life saved |
Brazilian Unified Health System |
$ 37,720/year of life saved |
| Colantonio et al. (2009) [20] |
MEDLINE |
Markov model |
Mass vaccination of pre-adolescent girls against HPV |
Population screening with OC |
QALY |
US$/QALY |
Brazilian Unified Health System |
$ 10,181/QALY |
| Kawai et al. (2012) [21] |
MEDLINE |
Dynamic transition model |
Mass quadrivalent vaccination of pre-adolescent girls against HPV |
Population screening with OC |
QALY |
US$/QALY |
Brazilian Unified Health System |
$ 450/QALY |
£The main result refers to the incremental cost-effectiveness ratio of the main strategy tested in relation to the base strategy, considering the base case described in the
article. Legend: OC: Oncotic Cytology For Cervical Cancer; QALY: Quality-Adjusted Life Years; SUS (Brazilian Unified Health System); ASC-US: Atypical Squamous Cells
of Unknown Significance